FDA Brief

Warning letters Drugs

FDA warning letter to

Curex

High riskIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.

What happened

FDA reviewed Curex's website at https://getcurex.com in August 2025; this was a website review, not an inspection. FDA observed that the site offers various compounded drug products, including semaglutide and tirzepatide, and makes claims such as “clinically proven” and “the same active ingredients as Ozempic or Mounjaro.” FDA says compounded drugs are not FDA-approved, so these claims misbrand the products.

What FDA found

  1. Curex's website labeling for compounded semaglutide and tirzepatide was false or misleading, including claims such as “clinically proven success.”

    FDCA section 502(a) [21 U.S.C. § 352(a)]
  2. Curex's advertising or promotion for compounded semaglutide and tirzepatide was false or misleading, including claims that the products have the same active ingredients as Ozempic or Mounjaro.

    FDCA section 502(bb) [21 U.S.C. § 352(bb)]
  3. Curex introduced or delivered misbranded compounded semaglutide and tirzepatide products into interstate commerce.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  4. The letter also states that receiving misbranded drugs in interstate commerce, and delivering or offering to deliver them, is prohibited.

    FDCA section 301(c) [21 U.S.C. § 331(c)]

What FDA wants

FDA tells Curex to take immediate action to stop using the cited misbranding language and to respond in writing within 15 working days to OCQC/CDER describing the steps taken, how it will prevent recurrence, and related documentation, or explain why it believes the products are not in violation.

Who should pay attention

  • telehealth companies selling compounded GLP-1 drugs
  • online pharmacies and compounding pharmacies
  • marketing and compliance teams for prescription drug websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk